ImmunityBio Inc IBRX

ImmunityBio Inc is an American biopharmaceutical company based in San Diego, California, with global operations. Founded in 2014, the company has a focus on late-clinical-stage immunotherapy, developing novel treatments for advanced cancers and infectious diseases that can improve the lives of patients worldwide. Areas of focus within the firm include both treatments and vaccine technologies, with an emphasis on the development of human adenovirus vaccines.

The firm’s Executive Chairman Dr Patrick Soon-Shiong was responsible for inventing the world’s first protein nanoparticle drug, Abraxane, and has long been dedicated to investigating the mechanisms that activate the immune system to attack tumours that can otherwise go undetected by the body’s natural defence mechanisms. The ImmunityBio immunotherapy platform activates both the innate and adaptive (T-cell) immune systems with the aim of creating long-term immunological memory.

The company is engaged in the development of vaccines and other therapies targeted at the prevention and treatment of a range of serious and potentially life-threatening viruses, including human immunodeficiency virus (HIV), influenza, and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using human adenovirus (hAd5) vaccine technologies. The firm trades on the NASDAQ, where it is listed under the stock ticker IBRX.

Learn more about the IBRX share price performance on eToro.